Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
Vivesto currently lacks the financial resources and internal capabilities required to advance its programmes independently and has therefore initiated partnering discussions across both its veterinary and human health portfolios. Successful transactions could unlock significant value and reduce financing risk. However, partnering processes typically take time and offer limited external visibility, making both the timing and outcome uncertain.
Long term
6+ YEARS
The success of the pipeline remains central to Vivesto's ability to transition into a profitable company with recurring product revenues. However, given the early-stage nature of the portfolio, development risk remains considerable. As a result, future value creation will depend largely on continued clinical de-risking and the company's ability to secure partners capable of funding and advancing the programmes through later-stage development and commercialisation.
Clinical development of Paccal Vet and Cantrixil is at an early stage, with high risks of setbacks.
Competing programmes generating clinical data that could narrow the commercial window for the company’s assets.
Securing partnerships would likely provide short- and longer-term financing and important external validation of its assets.
If it cannot secure a partner, we see risk of additional financing being needed.
Price
Fair range high value
Fair range low value
The upper end of our fair value range is based on our SOTP analysis, using a WACC of 15%, while the lower end applies a discount rate of 30%. In both scenarios, we anticipate continued progress in its programmes. However, investor sentiment towards biotech remains weak in our lower-end scenario, in which we incorporate an increased financing risk. Our upper-end scenario assumes improved sentiment.
Our valuation of Vivesto is based on a risk-adjusted cash flow model (rNPV), where each project is assessed individually over its patent lifespan and then aggregated in our SOTP model. We focus on the company's active programme, Paccal Vet and Cantrixil.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB